For example, in BRAF-mutated malignant melanoma, the combination of BRAF inhibitor encorafenib and MEK inhibitor binimetinib was more effective than single agents, showing significant effect in delaying the onset of drug resistance and improving the overall survival rate of patients (60, 61). The gene discussed is BRAF; the disease is melanoma.